Cencora, Inc. Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Aug-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Cencora is a widely held public company whose ownership has shifted notably in recent years. No family or founder controls it, and voting power follows economic ownership. The largest holder is Vanguard, near 12 percent, followed by BlackRock and State Street, positions that reflect the company membership in the leading benchmarks.The distinctive feature of the register has been Walgreens Boots Alliance. Through a 2013 distribution partnership and the later sale of its Alliance Healthcare business to Cencora, Walgreens became the largest shareholder, holding roughly 15 percent. Facing its own financial pressures, Walgreens sold down that stake steadily toward the low single digits, removing what had been an anchor holder.For investors the ownership evolution is a normalization. With Walgreens no longer a dominant holder and leadership under chief executive Bob Mauch, Cencora now answers to a conventional dispersed base. That base holds management accountable for executing its shift toward higher-margin specialty and physician-services businesses.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Cencora shareholder base is anchored by passive institutional capital, led by Vanguard, BlackRock and State Street, with the declining Walgreens position historically a distinctive feature. As Walgreens sold shares, index funds absorbed much of the float, leaving a conventional institutional register.Active investors own Cencora as a scaled distributor pivoting toward specialty and oncology. In fiscal 2025 the company grew revenue 9 percent to 321.3 billion dollars, though GAAP earnings were pressured by a goodwill impairment on its PharmaLex business and opioid-related expenses, leaving adjusted earnings per share of 16.00 dollars, up 16 percent, as the cleaner measure. They focus on adjusted earnings and the growth of specialty distribution.Governance follows conventional norms with an independent board. Because no controlling owner remains, capital return through a rising dividend and buybacks, including repurchases of Walgreens shares, is a lever management uses to reward holders. The debate among owners has centered on distribution margins, opioid obligations and the returns from its specialty acquisitions.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|
Portfolio Analysis
Cencora competes through distribution scale complemented by specialty and physician-services businesses. Its US Healthcare Solutions segment is the core, distributing pharmaceuticals to pharmacies, health systems and providers and generating the large majority of revenue at the thin margins typical of wholesale distribution.International Healthcare Solutions extends the business abroad, bolstered by the 2021 acquisition of Alliance Healthcare from Walgreens, and includes the specialty logistics provider World Courier. These operations diversify the company geographically and add higher-value specialty services.The strategic push is into specialty and physician services. Through the 2025 acquisition of Retina Consultants of America and the announced OneOncology deal, Cencora is building management-services organizations in ophthalmology and oncology, moving closer to specialty drug economics. The portfolio strategy leans on distribution scale for cash generation while growing specialty franchises that carry better margins.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|
Competitive Analysis
Cencora is one of the Big Three pharmaceutical distributors in the United States, together with McKesson and Cardinal Health, which control the overwhelming majority of the country drug supply. With fiscal 2025 revenue of 321.3 billion dollars, it is the second largest of the three and a scaled competitor in a concentrated industry.Its competitive edge is distribution scale and efficiency, reinforced by a long-standing relationship with Walgreens and by growing specialty capabilities. In a low-margin business, that scale and its specialty logistics and physician-services franchises differentiate it and provide exposure to higher-margin specialty drugs.The risks mirror those of its peers, thin distribution margins, opioid-settlement obligations and pressure from consolidating customers, alongside integration risk from its specialty acquisitions. Cencora competitive answer is its scale, its international footprint and its deliberate build-out of specialty and oncology services, which management argues will lift margins and growth over time.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|
Acquisitions Analysis
Cencora has used acquisitions to expand internationally and, more recently, to build specialty physician-services businesses. The transformative deal was the 2021 acquisition of Alliance Healthcare from Walgreens Boots Alliance for roughly 6.5 billion dollars, which greatly expanded its international distribution footprint.The recent focus is specialty and oncology. The 2025 acquisition of Retina Consultants of America for roughly 4.6 billion dollars gave Cencora a leading retina management-services organization, and the announced OneOncology transaction, valued near 7.4 billion dollars, would add a major community oncology network, moving the company deeper into specialty economics.The acquisition philosophy is to complement low-margin distribution with higher-value services and international scale. These deals carry integration and financing risk, reflected in interest expense and a goodwill impairment on the earlier PharmaLex purchase, but they reposition Cencora toward the faster-growing, higher-margin specialty end of healthcare.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Cencora structural history begins with a merger and includes a notable rename. The company was formed in 2001 as AmerisourceBergen through the combination of AmeriSource Health and Bergen Brunswig, creating one of the largest US drug distributors from two established wholesalers.The most significant later structural event was the 2021 acquisition of Alliance Healthcare from Walgreens Boots Alliance, which expanded the company international footprint and deepened the Walgreens partnership. In 2023 the company rebranded from AmerisourceBergen to Cencora to reflect its broader, more international healthcare ambitions.Recent structural moves have added specialty physician-services businesses through the Retina Consultants of America acquisition and the announced OneOncology deal. The pattern is one of building scale and international reach through distribution combinations, then layering on specialty services to move up the value chain.
Ownership History
Ownership History Analysis
Cencora traces its corporate origin to 2001, when AmeriSource Health and Bergen Brunswig merged to form AmerisourceBergen, combining two drug-distribution lineages that reached back much further into the twentieth century. The merger created a national distributor at the scale needed to serve the modern pharmaceutical supply chain.Over the following two decades the company grew through the drug-distribution boom, forged a defining partnership with Walgreens in 2013, and expanded internationally by acquiring Alliance Healthcare in 2021. In 2023 it rebranded as Cencora, signaling a broader healthcare identity beyond wholesale distribution.Today Cencora is the second largest US pharmaceutical distributor, led by chief executive Bob Mauch, with fiscal 2025 revenue of 321.3 billion dollars and a growing specialty business. Its history is one of consolidation in drug distribution, a deep Walgreens partnership, and a recent pivot toward specialty and physician services.
Ownership Explained
Cencora, formerly AmerisourceBergen, is a widely held public company listed on the New York Stock Exchange. Its largest owners are index managers, led by Vanguard, with BlackRock and State Street also prominent. Bob Mauch serves as president and chief executive officer. Walgreens Boots Alliance was long the largest shareholder through a distribution partnership, but it has reduced its stake from roughly 15 percent toward the low single digits.
With ownership now dispersed after Walgreens selldown, Cencora answers to public shareholders and the capital markets on a one-share one-vote basis. That accountability supports a strategy of leveraging distribution scale while building specialty, oncology and physician-services businesses. Management returns capital through dividends and buybacks. The steady exit of Walgreens as an anchor holder has left the register conventional, with no single controlling owner.